With Cancer, Time Matters.

Designated an FDA Breakthrough Therapy for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS), the novel immunotherapy ANKTIVA® activates key killer cells of the body’s natural immune system to attack the bladder cancer, allowing some people to live cancer free for more than 47 months.¹

The Power of ANKTIVA®

In the pivotal clinical trial, treatment of participants with BCG-unresponsive NMIBC CIS with or without papillary disease with ANKTIVA plus BCG was found to be well-tolerated and effective.¹

Proven Durability
Duration of Response
47+ Months
(Represents the upper limit of the range of duration of response)

1. ANKTIVA Package insert. lmmunityBio, Inc.; 2024.

Getting Started with ANKTIVA for Patients

A patient-friendly overview of how ANKTIVA plus BCG work together, as well as what patients should expect before and after treatment

Download

Patient Stories

Read about patients who participated in the clinical trials for ANKTIVA

Irv’s Journey

He was first diagnosed with bladder cancer in 2016, when  on Thanksgiving day, he had several concerning symptoms including blood in his urine. Several tumors on the interior surface of his bladder were removed by his local urologist,  who treated him with BCG. Unfortunately, he failed to respond and the tumors came back. He was afraid he was going to lose his bladder.

Learn More

Wayne’s Journey

Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who “just likes people”. When he was first told, “you might have a tumor in your bladder”, he became very concerned, especially when he learned his first treatment with BCG wasn’t working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.

Learn More

See All Stories

ANKTIVA Resources

Learn more about the clinical story of ANKTIVA

Peer-reviewed Paper

Future Oncology

A plain language review of the published findings on the Phase 1b BCG-naïve and Phase 2/3 BCG-unresponsive studies (QUILT 3.032).

Download PDF

Indication and Important Safety Information

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatchor call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA is a Novel Treatment for NMIBC CIS Patients Unresponsive to BCG

For more information, please call 1-877-ANKTIVA